Inventor · disambiguated record
Christophe Lurquin
Also filed as: LURQUIN CHRISTOPHE
18 granted patents·1 pending application·654 citations·filing 1991–2004
95Inventor score
Files withLUDWIG INST CANCER RES18
Top patents by PatentIndex Score
19 records- 0196US5342774ANucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1LUDWIG INST CANCER RES·Filed 1991·Granted Aug 30, 1994·232 cites·18 claims
- 0294US5405940AIsolated nonapeptides derived from MAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 1992·Granted Apr 11, 1995·129 cites·9 claims
- 0378US6034214AIsolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cellsLUDWIG INST CANCER RES·Filed 1994·Granted Mar 7, 2000·40 cites·4 claims
- 0478US5462871AIsolated nucleic acid molecules which encode MAGE derived nonapeptidesLUDWIG INST CANCER RES·Filed 1993·Granted Oct 31, 1995·52 cites·16 claims
- 0577US5587289AIsolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Dec 24, 1996·28 cites·12 claims
- 0675US6531451B1Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 1999·Granted Mar 11, 2003·24 cites·2 claims
- 0775US5925729ATumor rejection antigen precursors, tumor rejection antigens and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jul 20, 1999·31 cites·1 claims
- 0870US6407063B1Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 1998·Granted Jun 18, 2002·27 cites·8 claims
- 0969US6488932B1Method for treating cancer by administering MAGE-derived peptidesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 3, 2002·25 cites·4 claims
- 1069US6017705AIsolated nucleic acid molecules which are members of the MAGE-B family and uses thereofLUDWIG INST CANCER RES·Filed 1997·Granted Jan 25, 2000·15 cites·8 claims
- 1166US7351409B2Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 2004·Granted Apr 1, 2008·3 cites·2 claims
- 1257US5763155AMethod for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 gene productsLUDWIG INST CANCER RES·Filed 1996·Granted Jun 9, 1998·16 cites·2 claims
- 1351US5759783AMethod of screening for cancer by detecting messenger RNA for a MAGE-XP geneLUDWIG INST CANCER RES·Filed 1996·Granted Jun 2, 1998·11 cites·6 claims
- 1450US5763165AMethod for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3LUDWIG INST CANCER RES·Filed 1994·Granted Jun 9, 1998·14 cites·11 claims
- 1548US6710172B1Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 1999·Granted Mar 23, 2004·7 cites·1 claims
- 1633US6392016B1Isolated protein molecules which are members of the MAGE-B familyLUDWIG INST CANCER RES·Filed 1999·Granted May 21, 2002·0 cites·7 claims
- 1732US7923534B1Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3LUDWIG INST CANCER RES·Filed 1997·Granted Apr 12, 2011·0 cites·3 claims
- 1831USRE40089ENucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1996·Granted Feb 19, 2008·0 cites·25 claims
- 1926US2003082150A1Recombinant adenoviral vectors for human tumour gene therapyFiled 1997·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christophe Lurquin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →